Drugs / Pacritinib
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VONJO | — | 2022-02-28 | fda.gov ↗ |
Trials 53
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06414681 | Aug 2025 → Dec 2026 expected | myelofibrosis | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT07679334 | Aug 2026 → Aug 2028 expected | myeloproliferative neoplasm | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06675123 | Jun 2026 → Mar 2028 expected | mantle cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06538181 | Feb 2025 → Mar 2027 expected | VEXAS syndrome | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06218628 | Apr 2024 → Aug 2029 expected | acquired polycythemia vera, chronic myelomonocytic leukemia, essential thrombocythemia, myelofibrosis +1 | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05657613 | Jan → Jun 2023 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT05552183 | Dec 2022 → Jun 2024 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT03601819 | May 2019 → Mar 2020 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, lymphoproliferative syndrome, mantle cell lymphoma +2 | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02564536 | Jun 2017 → Jun 2020 | atypical chronic myeloid leukemia, BCR-ABL1 negative, juvenile myelomonocytic leukemia, myelodysplastic syndrome, myelofibrosis | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02323607 | Jan 2016 → Jul 2018 | therapy related acute myeloid leukemia and myelodysplastic syndrome | Bhavana Bhatnagar | Completed | No outcome recorded |
| Phase 1 | NCT02342353 | May 2015 → Feb 2018 | non-small cell lung carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT02807116 | Jan → Feb 2015 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02765724 | Jan → Jun 2015 | myelofibrosis | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02808455 | Jan → Mar 2015 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02807077 | Nov 2014 → Jul 2015 | myelofibrosis | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02807207 | Oct → Dec 2014 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02807051 | Sep → Oct 2014 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02803762 | Jul → Oct 2014 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00741871 | Jul 2008 → Oct 2011 | B-cell non-Hodgkin lymphoma, Hodgkins lymphoma | S*BIO | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT06303193 | Oct 2026 → Jan 2030 expected | myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07387354 | Jul 2026 → Jan 2027 expected | myelodysplastic syndrome, myeloproliferative neoplasm | Thomas Jefferson University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06516887 | Dec 2024 → May 2026 | lung adenocarcinoma | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 1/2 | NCT06159491 | Sep 2024 → Jul 2027 expected | chronic myelomonocytic leukemia | Douglas Tremblay | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05531786 | Mar 2023 → Jul 2027 expected | chronic graft versus host disease | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04520269 | Jul 2020 → Jul 2026 overdue | breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02891603 | Jun 2017 → Jan 2022 | acute graft versus host disease | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02677948 | Oct 2016 → Oct 2018 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00745550 | Aug 2008 → Jan 2012 | essential thrombocythemia, myelofibrosis, polycythemia | S*BIO | Completed | No outcome recorded |
| Phase 1/2 | NCT00719836 | Aug 2008 → Jan 2012 | acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome +1 | S*BIO | Completed | No outcome recorded |
| Phase 221 trials · 1 missed | ||||||
| Phase 2 | NCT07226713 | Sep 2026 → Mar 2029 expected | prostate cancer | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT07447817 | May 2026 → May 2030 expected | myelofibrosis | John Mascarenhas | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07394153 | Apr 2026 → Dec 2027 expected | myelofibrosis | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | Recruiting | No outcome recorded |
| Phase 2 | NCT07148947 | Mar 2026 → Dec 2028 expected | myeloproliferative neoplasm | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT07033598 | Jan 2026 → Jul 2028 expected | chronic myelomonocytic leukemia | Theradex | Recruiting | No outcome recorded |
| Phase 2 | NCT06986174 | Nov 2025 → Oct 2028 expected | Waldenstrom macroglobulinemia, lymphoproliferative syndrome | Shayna Sarosiek, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06782373 | May 2025 → Dec 2026 expected | VEXAS syndrome | Swedish Orphan Biovitrum | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06052618 | Mar 2025 → Jan 2033 expected | KSHV inflammatory cytokine syndrome, multicentric Castleman disease | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04858256 | Mar 2023 → Nov 2027 expected | T-cell and NK-cell neoplasm, lymphoproliferative syndrome | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04635059 | Jun 2021 → Nov 2023 | prostate cancer | Medical College of Wisconsin | Terminated | No outcome recorded |
| Phase 2 | NCT04404361 | May 2020 → Sep 2021 | COVID-19 | CTI BioPharma | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04282187 | Mar 2020 → Nov 2027 expected | acquired polycythemia vera, acute myeloid leukemia, essential thrombocythemia, myelodysplastic syndrome +4 | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT03645824 | Jun 2018 → Jul 2023 overdue | myelofibrosis | HOVON Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04884191 | Jul 2017 → Sep 2019 | myelofibrosis, primary myelofibrosis | CTI BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT02584777 | Nov 2015 → Sep 2017 | primary myelofibrosis | Baxalta now part of Shire | Withdrawn | No outcome recorded |
| Phase 2 | NCT02469415 | Sep 2015 → Jun 2017 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02277093 | Sep 2015 → Mar 2016 | colorectal cancer | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT02410551 | Jun 2015 → Jan 2017 | myeloproliferative neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01620216 | May 2012 → Apr 2017 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01436084 | Dec 2011 → Jun 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01263899 | Dec 2010 → Feb 2012 | Hodgkins lymphoma, indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma | S*BIO | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT03165734 | Jun 2017 → Oct 2026 expected | myelofibrosis, primary myelofibrosis | Swedish Orphan Biovitrum | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02055781 | Feb 2014 → Apr 2016 | myelofibrosis, primary myelofibrosis | CTI BioPharma | Terminated | Mixed |
| Phase 3 | NCT01773187 | Jan 2013 → Jan 2015 | myelofibrosis, primary myelofibrosis | CTI BioPharma | Terminated | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05980806 Background | Apr 2024 → Jun 2027 expected | myelofibrosis, thrombocytopenia | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT02532010 Comparator | Jun 2015 → Feb 2016 | acute myeloid leukemia | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Sobi, Inc. | Results Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025 sobi.com ↗
We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Sobi, Inc. | Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025 sobi.com ↗ |
| 2023-07-14 | Sobi, Inc. | Sobi KOL investor event: the journey for Vonjo® sobi.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pacritinib | “Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects” NCT02808455 ↗51“Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1.” PMID 25762180 ↗ Mar 2015 “Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |
| Known as | ONX-0803 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035187 ↗ |
| Known as | PAC | “Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).” NCT06414681 ↗ |
| Known as | PACRITINIB CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035187 ↗ |
| Known as | SB-1518 CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035187 ↗ |
| Known as | SB1518 | “Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1.” PMID 25762180 ↗ Mar 20154“Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |
| Known as | Vonjo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035187 ↗ |
| Action | Inhibit | “Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |
| Modality | Small molecule | “Pacritinib is an oral kinase inhibitor” NCT07387354 ↗ |
| Route | Oral | “SB1518 taken orally daily for 28 consecutive days in a 28-day cycle” NCT00719836 ↗ |
| Target | FLT3 | “Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |
| Target | IRAK1 | “Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |
| Target | JAK2 | “Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R.” PMID 27931243 ↗ Dec 2016 |